PIH and PIH-affiliated clinicians discuss the case of the first patient in Kazakhstan to receive a new treatment regimen that includes Bedaquiline. (Photo by Askar Yedilbayev / Partners In Health)
PIH and PIH-affiliated clinicians discuss the case of the first patient in Kazakhstan to receive a new treatment regimen that includes Bedaquiline. (Photo by Askar Yedilbayev / Partners In Health)

endTB Observational Study

      Principal Investigators

  • Helena Huerga (Epicentre)
  • KJ Seung (Partners In Health)
  • Uzma Khan (Interactive Research & Development)

endTB Clinical Trials

      Principal Investigators

  • Carole Mitnick (Harvard Medical School) 
  • Lorenzo Guglielmetti (Médecins sans Frontières)

      Co-Investigators 

  • Bouke de Jong (Antwerp Institute of Tropical Medicine) 
  • Elisabeth Baudin (Epicentre)
  • Francis Varaine (Médecins sans Frontières)
  • Gabriella Ferlazzo (Médecins sans Frontières)
  • Gustavo Velásquez (Harvard Medical School)
  • KJ Seung (Partners In Health)
  • Maryline Bonnet (Epicentre)
  • Michael Rich (Partners In Health)
  • Payam Nahid (University of California San Francisco) 
  • Uzma Khan (Interactive Research & Development)

      Site Principal Investigators 

  • Elmira Berikova, Aydarkhan Karabayev, Dakenova Zhanna, Sagit Bektasov (Kazakhstan)
  • Lawrence Oyewusi, Meseret Tamirat (Lesotho) 
  • Leonid Lecca, Dante Elmo Vargas Vásquez, Epifanio Sánchez Garavito, Eduardo Ticona (Peru) 
  • Nana Kiria (Georgia) 
  • Naseem Salahuddin (Pakistan) 
  • Nguyen Viet Nhung, Pham Huu Thuong, Phan Thuong Dat Pham Ngoc (Vietnam) 
  • Samiran Panda, Chetankumar Jain, Sandip Patil, Padmaja Jogewar, Vijay Chavan (India) 
  • Sean Wasserman (South Africa) 
PIH MSF MSF Unitaid: Save Lives Faster Médecins Sans Frontières (MSF) Transformational Investment Capacity (TIC) logo